ES2101073T3 - Nuevos aza-androstano-derivados 17-beta-substituidos. - Google Patents

Nuevos aza-androstano-derivados 17-beta-substituidos.

Info

Publication number
ES2101073T3
ES2101073T3 ES92810766T ES92810766T ES2101073T3 ES 2101073 T3 ES2101073 T3 ES 2101073T3 ES 92810766 T ES92810766 T ES 92810766T ES 92810766 T ES92810766 T ES 92810766T ES 2101073 T3 ES2101073 T3 ES 2101073T3
Authority
ES
Spain
Prior art keywords
formula
group
androstano
beta
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92810766T
Other languages
English (en)
Inventor
Michel Dr Biollaz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG, Novartis AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of ES2101073T3 publication Critical patent/ES2101073T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPUESTOS DE LA FORMULA, DONDE LOS ATOMOS DE CARBONO 1 Y 2 ESTAN UNIDOS POR MEDIO DE UN ENLACE SENCILLO O UN DOBLE ENLACE, R1 EQUIVALE A HIDROGENO, METILO O ETILO, Y A EQUIVALE A UN GRUPO DE FORMULA O C1 CLOALQUILENO; UN GRUPO DE FORMULA R2 TIENE EL SIGNIFICADO DADO ARRIBA, Y ES UN ENLACE DIRECTO O UN C1 ADO EL CASO SUSTITUIDO; UN GRUPO DE FORMULA TIENE EL SIGNIFICADO DADO ARRIBA, O EQUIVALE A UN GRUPO Y INHIBIDORES DE LA 5O TRATAMIENTOS TERAPEUTICOS DE CUERPOS HUMANOS Y DE ANIMALES.
ES92810766T 1991-10-09 1992-10-08 Nuevos aza-androstano-derivados 17-beta-substituidos. Expired - Lifetime ES2101073T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH297891 1991-10-09

Publications (1)

Publication Number Publication Date
ES2101073T3 true ES2101073T3 (es) 1997-07-01

Family

ID=4245915

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92810766T Expired - Lifetime ES2101073T3 (es) 1991-10-09 1992-10-08 Nuevos aza-androstano-derivados 17-beta-substituidos.

Country Status (19)

Country Link
US (2) US5304562A (es)
EP (1) EP0538192B1 (es)
JP (1) JPH05213989A (es)
KR (1) KR930007969A (es)
AT (1) ATE152121T1 (es)
AU (1) AU657579B2 (es)
CA (1) CA2080054A1 (es)
DE (1) DE59208383D1 (es)
DK (1) DK0538192T3 (es)
ES (1) ES2101073T3 (es)
FI (1) FI924529A7 (es)
GR (1) GR3024013T3 (es)
HU (1) HUT62600A (es)
IL (1) IL103361A (es)
MX (1) MX9205792A (es)
NO (1) NO923911L (es)
NZ (1) NZ244640A (es)
TW (1) TW263513B (es)
ZA (1) ZA927747B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives
CZ283894A3 (en) * 1992-05-20 1995-09-13 Merck & Co Inc 7beta-substituted 4-aza-5alpha-cholestanones, their use for the preparation of pharmaceutical preparations and pharmaceutical compositions containing thereof
AU4251993A (en) * 1992-05-20 1993-12-13 Merck & Co., Inc. Substituted 4-aza-5A-androstan-ones as 5A-reductase inhibitors
GB9210880D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Corp Compounds
GB9216284D0 (en) * 1992-07-31 1992-09-16 Erba Carlo Spa Fluorinated 17beta-substituted 4-aza-5alpha-androstane-3-one derivatives
HU212459B (en) * 1992-10-02 1996-06-28 Richter Gedeon Vegyeszet Process for producing new 17-beta-substituted 4-aza-androstane-derivatives and pharmaceutical compositions containing them
DE69329933T2 (de) * 1992-10-06 2001-07-19 Merck & Co., Inc. 17-beta-carboxanilid derivate von 4-aza-5-alpha-androstan-3-one als 5-alpha-reduktase-hemmende arzneimittel
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW408127B (en) * 1993-09-17 2000-10-11 Glaxo Inc Androstenones
US5470976A (en) * 1994-09-07 1995-11-28 Merck & Co., Inc. Process for the stereoselective reduction of steroid enelactams
US5543417A (en) * 1994-10-21 1996-08-06 Merck & Co., Inc. Combination method of treating acne using 4-AZA-5α-cholestan-ones and 4-AZA-5α-androstan-ones as selective 5α-reductase inhibitors with anti-bacterial, keratolytic, or anti-inflammatory agents
US5595996A (en) * 1994-10-25 1997-01-21 Merck & Co., Inc. 7-substituted 4-aza cholanic acid derivatives and their use
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
US6001844A (en) * 1995-09-15 1999-12-14 Merck & Co., Inc. 4-Azasteroids for treatment of hyperandrogenic conditions
CA2231041A1 (en) * 1995-09-15 1997-03-20 Raman K. Bakshi 4-azasteroids for treatment of hyperandrogenic conditions
US5998427A (en) * 1998-05-14 1999-12-07 Glaxo Wellcome Inc. Androstenones
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4377584A (en) * 1978-04-13 1983-03-22 Merck & Co., Inc. 4-Aza-17β-substituted-5α-androstan-3-one-reductase inhibitors
US5049562A (en) * 1984-02-27 1991-09-17 Merck & Co., Inc. 17β-acyl-4-aza-5α-androst-1-ene-3-ones as 5α-reductase inhibitors
US4760071A (en) * 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
IL74365A (en) * 1984-02-27 1990-07-26 Merck & Co Inc 17beta-(n-t.-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one and pharmaceutical compositions containing it
GB8505862D0 (en) * 1985-03-07 1985-04-11 Erba Farmitalia Steroidic 5alpha-reductase inhibitors
US4845104A (en) * 1986-11-20 1989-07-04 Merck & Co., Inc. Oxidized analogs of 17β-N-monosubstituted-carbamoyl-4-aza-5-α-androstan-3-ones
EP0271219B1 (en) * 1986-11-20 1992-07-29 Merck & Co. Inc. Topical pharmaceutical composition containing 17-beta-methoxycarbonyl-4-methyl-4-aza-5-alpha-androst-1-en-3-one
US4888336A (en) * 1987-01-28 1989-12-19 Smithkline Beckman Corporation Steroid 5-alpha-reductase inhibitors
EP0285383B1 (en) * 1987-04-03 1994-03-16 Merck & Co. Inc. Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
US5237061A (en) * 1988-10-31 1993-08-17 Merck & Co., Inc. Methods of synthesizing benign prostatic hypertropic agents and their intermediates
HUT60280A (en) * 1989-07-07 1992-08-28 Endorecherche Inc Process for producing androgen derivatives inhibiting sexual steroidal activity, as well as pharmaceutical compositions comprising same
CA2023157A1 (en) * 1989-08-21 1991-02-22 Gary H. Rasmusson 17 beta-acyl-4-aza-5 alpha-androst-1-ene-3-ones as 5 alpha-reductase inhibitors
US5120847A (en) * 1990-08-27 1992-06-09 Merck & Co., Inc. Process for iodinating or brominating the α-methylenic carbon of a secondary amide
IE76452B1 (en) * 1990-10-29 1997-10-22 Sankyo Co Azasteroid compounds for the treatment of prostatic hypertrophy their preparation and use
US5304562A (en) * 1991-10-09 1994-04-19 Ciba-Geigy Corporation 17β-substituted Aza-androstane derivatives

Also Published As

Publication number Publication date
TW263513B (es) 1995-11-21
NZ244640A (en) 1994-12-22
HUT62600A (en) 1993-05-28
EP0538192A1 (de) 1993-04-21
IL103361A0 (en) 1993-03-15
ZA927747B (en) 1993-04-13
ATE152121T1 (de) 1997-05-15
MX9205792A (es) 1993-08-01
AU657579B2 (en) 1995-03-16
DK0538192T3 (da) 1997-05-20
IL103361A (en) 1997-06-10
EP0538192B1 (de) 1997-04-23
NO923911D0 (no) 1992-10-08
US5378710A (en) 1995-01-03
GR3024013T3 (en) 1997-10-31
US5304562A (en) 1994-04-19
NO923911L (no) 1993-04-13
FI924529A0 (fi) 1992-10-07
KR930007969A (ko) 1993-05-20
AU2626192A (en) 1993-04-22
CA2080054A1 (en) 1993-04-10
HU9203189D0 (en) 1992-12-28
DE59208383D1 (de) 1997-05-28
FI924529A7 (fi) 1993-04-10
JPH05213989A (ja) 1993-08-24

Similar Documents

Publication Publication Date Title
ES2101073T3 (es) Nuevos aza-androstano-derivados 17-beta-substituidos.
ES2188584T3 (es) Derivados heterociclicos de amina.
ES2117123T3 (es) Derivados de aminocetilmercaptoacetilamida utilizados como inhibidores de la encefalinasa y del enzima de conversion de angiotensina.
ES2097872T3 (es) Fenilpirazolidinonas como agentes broncodilatadores y antiinflamatorios.
NZ325449A (en) Naphthyl-substituted benzimidazole derivatives as anticoagulants
MX9700249A (es) Compuestos ariltios como agentes antibacteriales yantivirales.
DE69519469D1 (de) Chinazolin-derivate
SV1999000059A (es) Compuestos farmaceuticos casa n.g. 1327
ES2164088T3 (es) Antagonistas de la sustancia p para el tratamiento de la emesis.
ES2143487T3 (es) 1,2,4-oxadiazolil-fenoxialquilisoxazoles y su empleo como agentes antivirales.
ES2110260T3 (es) Androstenonas.
ES2071325T3 (es) Derivados de 4-alquilimidazol.
ES2187565T3 (es) Alcaloides indolicos utiles como agentes antiinflamatorios.
ES2056073T3 (es) Aril-aralquil-eteres, procedimientos para su preparacion y composicion farmaceutica que los comprende.
FI903936A0 (fi) Saett att behandla hypertrofi och hyperplasi i hjaerta och blodkaerl.
MX9300250A (es) Metodo para emplear piridobenzodiazepinonas antimuscarinicas m1-selectivas en terapia de miopia axial.
ES2032482T3 (es) Derivados del bencilidenamino-, bencilamino- y benzoilamino-imidazol y su empleo como medicamentos. (reserva del art. 167.2 cpe).
DE60105028D1 (de) Ruthenium (ii) verbindungen in der krebsbehandlung
MX9300306A (es) Bencimidazoles medicamentos que contienen estos compuestos y procedimiento para su preparacion.
UY24009A1 (es) Compuestos ariltio útiles como agentes antivirales y antibacteriales
ATE153657T1 (de) Cyclische benzylamino-, benzylamido- und benzylimido derivate als antipsychotische wirkstoffe
ES2195468T3 (es) Cetonas insaturadas y su utilizacion en perfumeria.
ES2001006A4 (es) Compuestos sustituidos de 2,6-piridina sustituida
ES2078723T3 (es) 3-acilamino-2-pirrolidinonas como potenciadores de los procesos de aprendizaje y de la memoria y composiciones farmaceuticas que las contienen.
ES2157498T3 (es) Derivados de triazol o sus sales.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 538192

Country of ref document: ES